Joanne Bal
- The pharmacokinetics (PK) of fluticasone furoate (FF) in healthy Caucasian, Chinese, Japanese and Korean subjectsBy Ann Allen, Joanne Bal, Anne Cheesbrough, Melanie Hamilton and Rodger KempsfordAnn Allen1Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline R&D, Stevenage, Hertfordshire, United KingdomJoanne Bal2Clinical Pharmacology Science & Study Operations, GlaxoSmithKline R&D, Stockley Park, Middlesex, United KingdomAnne Cheesbrough3Discovery Biometrics, GlaxoSmithKline R&D, Uxbridge, Middlesex, United KingdomMelanie Hamilton4Inhaled Product Development, GlaxoSmithKline R&D, Ware, Hertfordshire, United KingdomRodger Kempsford5Respiratory Medicine Development Centre, GlaxoSmithKline R&D, Stevenage, Hertfordshire, United Kingdom
- The effect of ketoconazole on the pharmacokinetics (PK) and pharmacodynamics (PD) of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in healthy subjectsBy Rodger Kempsford, Ann Allen, Joanne Bal, David Rubin and Lee TombsRodger Kempsford1Respiratory Medicines Development Centre, GlaxoSmithKline R&D, Stevenage, Hertfordshire, United KingdomAnn Allen2Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline R&D, Stevenage, Hertfordshire, United KingdomJoanne Bal3Clinical Pharmacology Science & Study Operations, GlaxoSmithKline R&D, Uxbridge, Middlesex, United KingdomDavid Rubin4Respiratory Medicines Development Centre, GlaxoSmithKline R&D, Research Triangle Park, NC, United StatesLee Tombs5Statistics & Programming, Satellite, Slough, Berkshire, United Kingdom
- The absolute bioavailability of fluticasone furoate (FF) and vilanterol (VI) trifenatate following inhaled administration in combination in healthy subjectsBy Ann Allen, Joseph Bianco, Joanne Bal, Lee Tombs and Rodger KempsfordAnn Allen1Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline R&D, Stevenage, Hertfordshire, United KingdomJoseph Bianco2Clinical Pharmacology Science & Study Operations, GlaxoSmithKline R&D, Randwick, New South Wales, AustraliaJoanne Bal3Clinical Pharmacology Science & Study Operations, GlaxoSmithKline R&D, Uxbridge, Middlesex, United KingdomLee Tombs4Statistics & Programming, Satellite, Slough, Berkshire, United KingdomRodger Kempsford5Respiratory Medicine Development Centre, GlaxoSmithKline R&D, Stevenage, Hertfordshire, United Kingdom
- The pharmacokinetics (PK) and pharmacodynamics (PD) of repeat inhaled administration of fluticasone furoate (FF) in healthy Caucasian, Chinese, Japanese and Korean subjectsBy Ann Allen, Joanne Bal, Anne Cheesbrough, Melanie Hamilton and Rodger KempsfordAnn Allen1Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline R&D, Stevenage, Hertfordshire, United KingdomJoanne Bal2Clinical Pharmacology Science & Study Operations, GlaxoSmithKline R&D, Stockley Park, Middlesex, United KingdomAnne Cheesbrough3Discovery Biometrics, GlaxoSmithKline R&D, Uxbridge, Middlesex, United KingdomMelanie Hamilton4Inhaled Product Development, GlaxoSmithKline R&D, Ware, Hertfordshire, United KingdomRodger Kempsford5Respiratory Medicine Development Centre, GlaxoSmithKline R&D, Stevenage, Hertfordshire, United Kingdom
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.
